| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | PGP-4008 Basic information |
| Product Name: | PGP-4008 | | Synonyms: | Recombinant Human p-Glycoprotein/MRP;PGP-4008;PGP-4408;N-(1-BENZYL-2,3-DIHYDRO-1H-PYRROLO[2,3-B]QUINOLIN-4-YL)-2-PHENYLACETAMIDE;Abcb1b;Mdr1b Rat;rodent multidrug resistance protein;Benzeneacetamide, N-[2,3-dihydro-1-(phenylmethyl)-1H-pyrrolo[2,3-b]quinolin-4-yl]- | | CAS: | 365565-02-2 | | MF: | C26H23N3O | | MW: | 393.48 | | EINECS: | | | Product Categories: | proteins | | Mol File: | Mol File |  |
| | PGP-4008 Chemical Properties |
| storage temp. | −20°C | | solubility | DMSO: 50mM; Ethanol: 5mM | | form | White to off-white powder. | | color | White to off-white |
| | PGP-4008 Usage And Synthesis |
| Description | PGP-4008 is a selective inhibitor of P-glycoprotein (P-gp) that does not affect the activity of multidrug resistance-related protein 1 (MRP1). It is effective in vitro and, when delivered intraperitoneally, in vivo, inhibiting tumor growth when given with doxorubicin . PGP-4008 also enhances the ability of docetaxel to inhibit growth and drive apoptosis in ovarian cancer cells. | | Uses | PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin[1]. | | References | [1] Brian D Lee, et al. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem. 2004 Mar 11;47(6):1413-22. DOI:10.1021/jm0303204 |
| | PGP-4008 Preparation Products And Raw materials |
|